Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

Inclusion Criteria:

Participants who meet all of the following criteria assessed at the time of enrollment are eligible for this study:

1. Ability and willingness to provide informed consent. For adult participants unableto provide informed consent, informed consent provided by the legally authorizedrepresentative (LAR).

2. Has a diagnosis of MM requiring systemic anti-myeloma therapy as per InternationalMyeloma Working Group (IMWG) criteria.

3. Initiated HyQvia treatment as part of routine clinical care no more than 30 daysbefore study enrollment or received no more than 2 doses of HyQvia treatment,whichever occurs first. Participants are also eligible if they newly start HyQviawithin 30 days after the enrollment visit. Note: Participants who do not start HyQvia treatment within 30 days of enrollmentwill be considered as screen failures (and replaced).

4. Age >=18 years old at the time of MM diagnosis.

5. Available medical history records starting from the diagnosis of MM requiringsystemic anti-myeloma therapy as IMWG criteria.

6. Life expectancy >6 months at the time of enrollment, per physician assessment.

7. Eastern Cooperative Oncology Group (ECOG) performance status score of <=2.

8. Participants/LAR willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

Participants who meet any of the following criteria assessed at the time of enrollment are not eligible for this study:

1. Known hypersensitivity to any of the components of HyQvia.

2. Primary immunodeficiency (PID) or diagnosed with human immunodeficiencyvirus/acquired immunodeficiency syndrome (HIV/AIDS) and/or active hepatitis C and/oractive hepatitis B infection.

3. Prior use of Ig treatment or prophylaxis within 3 months from the date ofenrollment.

4. Serious infection(s) requiring intravenous (IV) treatment at the time of enrollmentinto the study; except for participants on short-term oral antibiotic therapy.

5. Has participated in an interventional clinical study involving a medicinal productor device within 30 days prior to enrollment or is scheduled to participate in aninterventional clinical study involving a medical product or device during thisstudy. Note: Participants on investigational chimeric antigen receptor-T (CAR-T) celltherapies and/or bispecific antibodies may participate.

6. Planned stem cell transplant during the treatment period or had a prior stem celltransplant: allogeneic transplant at any time, autologous transplant within 3 monthsof enrollment.

7. History of malignancy (other than MM) within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ ofthe cervix or breast, localized prostate cancer or other non-invasive lesion that inthe opinion of the investigator, is considered cured with minimal risk of recurrencewithin 3 years).

8. Participant has had major surgery within 2 weeks before enrollment, or has not fullyrecovered from an earlier surgery, or has surgery planned during the time theparticipant is expected to participate in the study.

Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery.